Oral Steroids

Winstrol Oral (Stanozolol) 15mg

Winstrol Oral (Stanozolol) 15mg (15 mg) — Stanozolol has cemented its legacy as the definitive cutting and hardening compound in competitive bodybuilding. As a DHT derivati...

65,00

In Stock (100 available)

Medical Pharma · Winstrol Oral (Stanozolol) 15mg (15 mg) — Stanozolol has cemented its legacy as the definitive cutting and hardening compound in competitive bodybuilding. As a DHT derivati…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Winstrol Oral (Stanozolol) 15mg — stanozolol from the manufacturer at 15 mg. DHT derivative that cannot aromatise, uniquely reduces SHBG by up to 50% (freeing other steroids for greater effect). Injectable aqueous suspension or oil; either way cosmetic hardening shows within 1–2 weeks.

Key Benefits

  • 17α-alkylated DHT-derivative — zero aromatisation, no water retention
  • Significant SHBG reduction — frees up more bound testosterone on cycle
  • Dramatic strength and hardness gains without scale-weight bloat
  • Available oral OR aqueous injectable — same molecule, different kinetics
  • Cutting and pre-contest staple when dry, vascular look is the goal
  • Each unit dosed at 15 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: oral 25–50 mg/day for 6–8 weeks, or injectable 50 mg every other day. Women 5–10 mg/day oral, short cycles only (4 weeks) — virilisation risk rises sharply beyond that. Above 50 mg/day SHBG crashes hard and joint dryness becomes limiting.

How It Works

17α-alkylated DHT-derivative. Does not aromatise. Distinctive mechanism: significant SHBG reduction that frees more co-administered testosterone to bind the AR. Minimal progestagenic activity. Androgenic effects at typical dose are low, but hair-follicle impact in genetically predisposed users is measurable.

Pharmacokinetics

Oral half-life ~9 hours; aqueous-suspension injectable ~24 hours. The injectable is the same molecule as the tablet — the suspension simply bypasses first-pass liver metabolism. Hepatotoxicity similar between routes since the 17α-alkyl group is preserved in both. ALT/AST at week 4.

Potential Side Effects

Joint pain from reduced synovial fluid is the signature complaint — fish oil 4 g/day helps. Lipid panel takes a big hit (HDL drops 30–50%). Androgenic side-effects dose-dependent. Liver markers rise; mandatory TUDCA support.

Cycle & Stacking Guide

Cutting and pre-contest hardening, 6–8 weeks. Standard stack: test base + stanozolol + trenbolone or masteron. Not a mass-builder — use methandienone or oxymetholone for that role. Avoid heavy pressing during cycle if joints are pre-compromised.

Storage & Handling

Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Winstrol Oral (Stanozolol) 15mg”

Your email address will not be published. Required fields are marked *

Stanozolol

Physical & Chemical Properties for Research Purposes
Chemical structure of Stanozolol (C21H32N2O) for laboratory analysis
2D structural representation · PubChem CID 25249 ↗
Chemical Identity
# CAS Registry Number 10418-03-8
Σ IUPAC Name (1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-2,3,3a,3b,4,5,5a,6,10b,11,12,12a-dodecahydro-1H-cyclopenta[5,6]naphtho[1,2-f]indazol-1-ol
F Molecular Formula C21H32N2O
M Molecular Weight 328.49 g/mol
SMILES C[C@]1(O)CC[C@@H]2[C@H]3CCC4=CC5=CC=N[NH]5C[C@]4(C)[C@@H]3CC[C@]12C
InChIKey HCNHNBLBDSXWPN-UHFFFAOYSA-N
Melting Point 229-242 °C
Solubility Practically insoluble in water; soluble in dimethylformamide
Biological Half-life 9 hours (oral) / 24 hours (IM)
PubChem CID 25249 ↗
Pharmacological Profile
Anabolic Rating 320
Androgenic Rating 30
Aromatization None
Hepatotoxicity High
Detection Time 2 months

Clinical Notes

Heterocyclic DHT derivative — pyrazole fused to the A-ring, blocking 3alpha-HSD metabolism. Crushes SHBG in a dose-responsive manner (documented 40–50% reduction at 50 mg/day oral x 4 weeks), which is the proximate mechanism for its perceived amplification effect on co-administered androgens: bound testosterone is released, free-testosterone fraction rises. The compound itself has modest direct AR activity. Oral form is C17alpha-alkylated with predictable hepatotoxicity. Connective-tissue profile is the clinical liability: tendinopathy and ligament rupture frequency is elevated on stanozolol protocols. Joint lubrication complaint is universal above 40 mg/day and resolves on cessation. Lipid degradation is among the steepest in the oral class; HDL reductions of 50–60% at therapeutic doses are reproducible.

Known trade names: Winstrol, Stromba, Stanover

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.